Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 May 28

PMID 35625893

Authors

Raquel Alves

Ana Cristina Goncalves

Joana Jorge

Antonio M Almeida

Ana Bela Sarmento-Ribeiro

Affiliations

Soon will be listed here.

Abstract

Multidrug resistance (MDR) development has emerged as a complication that compromises the success of several chemotherapeutic agents. In chronic myeloid leukemia (CML), imatinib resistance has been associated with changes in and intracellular drug concentration, controlled by SLC and ABC transporters. We evaluate the therapeutic potential of a P-glycoprotein and BCRP inhibitor, elacridar, in sensitive (K562 and LAMA-84) and imatinib-resistant (K562-RC and K562-RD) CML cell lines as monotherapy and combined with imatinib. Cell viability was analyzed by resazurin assay. Drug transporter activity, cell death, cell proliferation rate, and cell cycle distribution were analyzed by flow cytometry. Both resistant models presented an increased activity of BCRP and P-gP compared to K562 cells. Elacridar as monotherapy did not reach IC in any CML models but activated apoptosis without cytostatic effect. Nevertheless, the association of elacridar (250 nM) with imatinib overcomes resistance, re-sensitizing K562-RC and K562-RD cells with five and ten times lower imatinib concentrations, respectively. Drug combination induced apoptosis with increased cleaved-caspases-3, cleaved-PARP and DNA damage, reduced cell proliferation rate, and arrested CML cells in the S phase. These data suggest that elacridar combined with imatinib might represent a new therapeutic option for overcoming TKI resistance involving efflux transporters.

Citing Articles

Contribution and expression of renal drug transporters in renal cell carcinoma.

Zuo Y, Li T, Yang S, Chen X, Tao X, Dong D Front Pharmacol. 2025; 15:1466877.

PMID: 40034145 PMC: 11873565. DOI: 10.3389/fphar.2024.1466877.

The Role of Elacridar, a P-gp Inhibitor, in the Re-Sensitization of PAC-Resistant Ovarian Cancer Cell Lines to Cytotoxic Drugs in 2D and 3D Cell Culture Models.

Stasiak P, Sopel J, Lipowicz J, Rawluszko-Wieczorek A, Korbecki J, Januchowski R Int J Mol Sci. 2025; 26(3).

PMID: 39940891 PMC: 11817197. DOI: 10.3390/ijms26031124.

A New Class of Gold(I) NHC Complexes with Proapoptotic and Resensitizing Properties towards Multidrug Resistant Leukemia Cells Overexpressing BCL-2.

Bannwart F, Richter L, Stifel S, Rueter J, Lode H, Correia J J Med Chem. 2024; 67(17):15494-15508.

PMID: 39196554 PMC: 11403678. DOI: 10.1021/acs.jmedchem.4c01117.

Batimastat Induces Cytotoxic and Cytostatic Effects in In Vitro Models of Hematological Tumors.

Alves R, Pires A, Jorge J, Balca-Silva J, Goncalves A, Sarmento-Ribeiro A Int J Mol Sci. 2024; 25(8).

PMID: 38674139 PMC: 11050270. DOI: 10.3390/ijms25084554.

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia.

Verhagen N, Koenderink J, Blijlevens N, Janssen J, Russel F Pharmaceutics. 2023; 15(11).

PMID: 38004514 PMC: 10675650. DOI: 10.3390/pharmaceutics15112535.

References

Hochhaus A, Saussele S, Rosti G, Mahon F, Janssen J, Hjorth-Hansen H . Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv41-iv51. DOI: 10.1093/annonc/mdx219. View

Nicolini F . CML stem cells: evasion for better invasion. Blood. 2017; 129(2):141-142. DOI: 10.1182/blood-2016-11-750554. View

Li W, Zhang H, Assaraf Y, Zhao K, Xu X, Xie J . Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat. 2016; 27:14-29. DOI: 10.1016/j.drup.2016.05.001. View

Planting A, Sonneveld P, van der Gaast A, Sparreboom A, van der Burg M, Luyten G . A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2004; 55(1):91-9. DOI: 10.1007/s00280-004-0854-6. View

Ali M . Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy. Mol Diagn Ther. 2016; 20(4):315-33. DOI: 10.1007/s40291-016-0208-1. View

de Gooijer M, de Vries N, Buckle T, Buil L, Beijnen J, Boogerd W . Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. Neoplasia. 2018; 20(7):710-720. PMC: 6030392. DOI: 10.1016/j.neo.2018.05.001. View

Ianevski A, Giri A, Aittokallio T . SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020; 48(W1):W488-W493. PMC: 7319457. DOI: 10.1093/nar/gkaa216. View

Huang F, Wu D, Zhang L, Yu Y, Yuan X, Li W . Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Cancer Lett. 2013; 336(1):96-105. DOI: 10.1016/j.canlet.2013.04.006. View

Chen H, Shien K, Suzawa K, Tsukuda K, Tomida S, Sato H . Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer. Oncol Lett. 2017; 14(4):4349-4354. PMC: 5607652. DOI: 10.3892/ol.2017.6678. View

10.

DeGorter M, Xia C, Yang J, Kim R . Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 2011; 52:249-73. DOI: 10.1146/annurev-pharmtox-010611-134529. View

11.

Hyafil F, Vergely C, du Vignaud P, Grand-Perret T . In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993; 53(19):4595-602. View

12.

Bar-Zeev M, Kelmansky D, Assaraf Y, Livney Y . β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer. Eur J Pharm Biopharm. 2018; 133:240-249. DOI: 10.1016/j.ejpb.2018.10.018. View

13.

Beretta G, Cassinelli G, Pennati M, Zuco V, Gatti L . Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. Eur J Med Chem. 2017; 142:271-289. DOI: 10.1016/j.ejmech.2017.07.062. View

14.

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

15.

Zhou S, Schuetz J, Bunting K, Colapietro A, Sampath J, Morris J . The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001; 7(9):1028-34. DOI: 10.1038/nm0901-1028. View

16.

Seigneurin D, Champelovier P, Mouchiroud G, Berthier R, Leroux D, PRENANT M . Human chronic myeloid leukemic cell line with positive Philadelphia chromosome exhibits megakaryocytic and erythroid characteristics. Exp Hematol. 1987; 15(8):822-32. View

17.

da Cunha Vasconcelos F, Scheiner M, Moellman-Coelho A, Mencalha A, Renault I, Rumjanek V . Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice. Leuk Res. 2016; 51:3-10. DOI: 10.1016/j.leukres.2016.10.005. View

18.

Silva R, Vilas-Boas V, Carmo H, Dinis-Oliveira R, Carvalho F, Bastos M . Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther. 2014; 149:1-123. DOI: 10.1016/j.pharmthera.2014.11.013. View

19.

De Bruin M, Miyake K, Litman T, Robey R, Bates S . Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 2000; 146(2):117-26. DOI: 10.1016/s0304-3835(99)00182-2. View

20.

Shukla S, Sauna Z, Ambudkar S . Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia. 2007; 22(2):445-7. DOI: 10.1038/sj.leu.2404897. View